{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:34:03Z","timestamp":1792074843984,"version":"4.4.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,7,3]],"date-time":"2002-07-03T00:00:00Z","timestamp":1025654400000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>Orthotopic liver transplantation (OLT) is effective therapy for end\u2010stage liver disease but immunosuppression with calcineurin inhibitors (CNI) leads to significant nephrotoxicity, resulting in either a reduction of dosage to below the therapeutic level or omission of the drug altogether. Basiliximab (Bx) is a human\/mouse chimeric monoclonal antibody that inhibits binding of interleukin\u20102 (IL\u20102) to IL\u20102 receptors and thus prevents proliferation of T cells, which is the main step in the development of acute cellular rejection. The aim of this study was to identify the role of Bx in the prevention of acute cellular rejection and in the reduction of nephrotoxicity in children post\u2010liver transplantation. We evaluated three children (19\u2003months, 22\u2003months, and 11\u2003yr of age; one male, two female) who were treated with Bx post\u2010OLT on compassionate grounds. The indications were: nephrotoxicity in two children, requiring re\u2010transplantation for hepatic artery thrombosis and recurrent giant cell hepatitis, respectively; and nephrotoxicity secondary to chemotherapy for hepatoblastoma in the third child. All patients received 10\u2003mg of Bx, at OLT and on Day 4. Tacrolimus (0.15\u2003mg\/kg\/day) was started at 48 h (n\u2003=\u20032) and cyclosporin (5\u2003mg\/kg\/day) at 2\u2003weeks (n\u2003=\u20031). Trough levels of tacrolimus were maintained at 5\u20138\u2003ng\/mL and trough levels of cyclosporin at 100\u2013150\u2003mg\/L for the first 3\u2003months. All patients received methylprednisolone (2\u2003mg\/kg) with azathioprine (1.5\u2003mg\/kg) (n\u2003=\u20032) and\/or mycophenolate mofetil (20\u2003mg\/kg) (n\u2003=\u20031). The glomerular filtration rate (cGFR) was calculated using the Schwartz formula before and 10\u2003weeks after transplant. Bx was found to be easy to administer and no major side\u2010effects were reported. One child had two episodes of mild acute rejection at 5 and 9\u2003weeks post\u2010OLT and one developed chronic rejection requiring re\u2010transplantation at 9\u2003weeks post\u2010OLT. One child did not develop rejection. The mean pretransplant cGFR was 58.1 (54.6\u201364.1)\u2003mL\/min\/m<jats:sup>2<\/jats:sup>. Within 10\u2003weeks of transplantation, the cGFR had improved by 69% to a mean of 116 (88\u2013157.6)\u2003mL\/min\/m<jats:sup>2<\/jats:sup>. To conclude, Bx was well tolerated in all children and had a renal sparing effect. It was effective in preventing early acute rejection, but the combination of Bx and low\u2010dose CNI drugs did not prevent late acute or chronic rejection. Further studies to evaluate the appropriate levels of CNI immunosuppression with Bx are required.<\/jats:p>","DOI":"10.1034\/j.1399-3046.2002.01076.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T18:59:08Z","timestamp":1047495548000},"page":"214-218","source":"Crossref","is-referenced-by-count":28,"title":["Concomitant basiliximab with low\u2010dose calcineurin inhibitors in children post\u2010liver transplantation"],"prefix":"10.1034","volume":"6","author":[{"given":"N.","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V.","family":"Beath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"DeVille De Goyet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,7,3]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410273311702"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1399-0012.1995.tb00357.x","article-title":"Rejection epis\u2010odes after liver transplantation during primary immuno\u2010suppression with FK506 or a cyclosporin\u2010based regimen: a controlled prospective randomised trial","volume":"9","author":"Jonas S","year":"1995","journal-title":"Clin Transpl"},{"key":"e_1_2_7_4_2","first-page":"930","article-title":"Organ trans\u2010plantation since the advent of Cyclosporin","volume":"68","author":"Du Toit DF","year":"1985","journal-title":"S Afr Med J"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-5-667"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808501900202"},{"issue":"1","key":"e_1_2_7_7_2","first-page":"5","article-title":"Cyclosporin: the agent and its actions","volume":"17","author":"Kahan BD","year":"1985","journal-title":"Transplant Proc"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1986.tb03538.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/clinchem\/35.4.564","article-title":"Cyclosporin concentration in blood after liver transplantation: corre\u2010lation of immunoassay results with clinical events","volume":"35","author":"Haven MC","year":"1989","journal-title":"Clin Chem"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(86)90035-4"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61034-9"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199608150-00011"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198336060-00010"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198902000-00025"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.1994.tb01286.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240518"},{"key":"e_1_2_7_17_2","first-page":"81","article-title":"The im\u2010pairment of true glomerular filtration rate in long term cyclosporin treated paediatric allograft recipients","volume":"49","author":"McDiarmid SV","year":"1990","journal-title":"Trans-plantation"},{"key":"e_1_2_7_18_2","first-page":"239","volume-title":"Cytokinesin: Cellu\u2010lar and Molecular Immunology","author":"Abbas AK","year":"1994"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199510150-00023"},{"key":"e_1_2_7_20_2","volume-title":"The American Society of Transplant Phys\u2010icians. 15th Annual Scientific Meeting.","author":"Kovarik J","year":"1997"},{"key":"e_1_2_7_21_2","first-page":"913","article-title":"Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation","volume":"28","author":"Koverik JM","year":"1996","journal-title":"Transplant Proc"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199911150-00012"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz GJ","year":"1976","journal-title":"Paediatrics"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.75.6.502"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90024-8"},{"key":"e_1_2_7_26_2","first-page":"243","article-title":"Basiliximab simplifying induction therapy","volume":"27","author":"Bell J","year":"2000","journal-title":"Nephrol Nurs J"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09278-7"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199901270-00016"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.21.3614"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02822-1"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3046.2002.01076.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3046.2002.01076.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:16:23Z","timestamp":1733717783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3046.2002.01076.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1034\/j.1399-3046.2002.01076.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3046.2002.01076.x","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}